维拉帕米和Na+/H+通道阻滞剂对大鼠肝脏热缺血再灌注损伤的影响及其机制

目的]研究维拉帕米(VP)和5-N-乙基-异丙基阿米洛利(EIPA)单独及联合作用对大鼠肝脏热缺血再灌注损伤保护作用及其机制.方法]50只SD大鼠随机分成空白组(A组),缺血再灌注组(B组),EIPA 缺血再灌注组(C组),维拉帕米 缺血再灌注组(D组),EIPA VP 缺血再灌注组(E组),每组10只.缺血前10 min自尾静脉注入药物.制备95%肝脏缺血模型,缺血30 min,再灌注2 h后取静脉血、肝脏标本,比较各组之间的肝功能(ALT, AST),肝组织匀浆XOD活性,肝组织Ca2 浓度以及肝组织形态学变化.结果]VP和EIPA组各项检测指标与缺血再灌注组比有显著性差异,联合用药组与单独用药组比较有显著性差异(P＜0.05).结论]维拉帕米和EIPA预处理能减轻肝脏缺血再灌注损伤,联合用药有协同保护作用,效果更明显.

Experimental Studies on Protective Effect of Na+/H+ Channel Blockers and Verapamil Injection Against Hepatic Ischemia Reperfusion Injury

Objective]To investigate effect of Na /H channel blockers EIPA and Verapamil injection on hepatic ischemia reperfusion injury in rats. Methods]Fifty SD rats were randomly divided into five groups (10 rats each group); Group A: normal control; Group B: ischemic reperfusion model; Group C: pretreated the ischemic-reperfusion model with EIPA. Group D: pretreated the ischemic reperfusion model with Verapamil; Group E: pretreated the ischemic reperfusion model with EIPA and Verapamil. All medicines were injected 10 minutes before ischemia from vena caudalis. The ischemic reperfusion model was produced by clamping the hepatic artery and portal vein with a clamp for 30 minutes then reperfusing for 2 hours. The hepatic tissues and blood samples were collected 2 hours after reperfusion. Then the XOD, Ca2 , ALT, AST were measured and hepatic tissue were sent for pathological examination. Results]Compared with Group B, the medicines in Group C, D, E had predominant effect on ischemia reperfusion injury. Compared with Group C, D, the data of Group E had significant difference (P<0.05). Conclusion]EIPA and Verapamil pretreatment could prevent and reduce the hepatic ischemia reperfusion injury. The protective effect will be more sigificant when combined with EIPA and Verapamil.